Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors

Core Viewpoint - Compugen has appointed Michele Holcomb, Ph.D., as an independent director to its Board of Directors, effective February 11, 2026, bringing over 30 years of experience in biotech, pharmaceuticals, and healthcare services [1] Group 1: Appointment Details - Michele Holcomb's extensive background includes strategic insights, corporate development, and operational experience, which will enhance Compugen's Board [1] - The appointment is expected to strengthen the company's ability to convert clinical opportunities into long-term value for patients and shareholders [1] Group 2: Company Overview - Compugen is a clinical-stage cancer immunotherapy company utilizing AI/ML for drug target discovery [1] - The company has multiple first-in-class clinical programs and partnerships, including two validating pharma partnerships [1] - Compugen's pipeline includes several differentiated programs targeting TIGIT and other novel drug targets [1] Group 3: Dr. Holcomb's Background - Dr. Holcomb has held significant roles, including EVP at Cardinal Health and COO at Teva Pharmaceuticals, focusing on strategy and business development [1] - She has experience in managing partnerships, acquisitions, and optimizing portfolios in the healthcare sector [1] - Dr. Holcomb serves on various boards and has a strong academic background with a BS and PhD in chemistry [1]